News | October 13, 2008

Data on Medtronic’s Endeavor Stent Shows Strong Performance in Complex Patients

October 14, 2008 – Medtronic released, at TCT 2008, new data from the ENDEAVOR clinical program that reinforces the consistently strong performance of the company’s Endeavor drug-eluting stent (DES) across diverse patient populations affected by coronary artery disease.

One-year results from the ENDEAVOR-Five registry – including those for subsets of diabetics and patients with acute myocardial infarction (AMI) – demonstrate that the Endeavor DES performs comparably in a real-world population of patients with complex disease and in specific patient subsets.

“Registries generally enroll more challenging ‘real-world’ patients than randomized trials,” said professor Martin Rothman of the U.K.’s London Chest Hospital and one of ENDEAVOR-Five’s principal investigators.

“Approximately 70 percent of the 8,314 patients enrolled in E-Five had complex cardiovascular disease, including diabetes, small vessels and long lesions, and a significant number were acute coronary syndrome or AMI. Despite the higher complexity of the patients enrolled in this registry, the outcomes at 12 months were excellent; the rates of MACE, TLR, cardiac death, MI and stent thrombosis were remarkably low and consistent with findings from the ENDEAVOR clinical trial program overall.”
The 12-month target lesion revascularization (TLR) rate for all patients in E-Five (n=8,314) was 4.5 percent; for the subset of diabetics (n=2,563), 5.3 percent; for the AMI patients (n=1,077), 3.2 percent; and for the high-risk patients (n=5,824), 5.0 percent.

Five-year results from the ENDEAVOR-I trial complement and corroborate a vast array of consistently compelling data, which supports the durable efficacy of the Endeavor DES over the long term, said Medtronic.

Medtronic’s Endeavor stent is associated with TLR rates, which stop increasing at three years. Randomized controlled trials of other drug-eluting stents show a continued increase in TLR, reducing the durability of benefit. More compelling is how the ENDEAVOR-I TLR plateau is replicated on a larger scale in ENDEAVOR-II, the device’s pivotal study. With data out to four years, exactly the same curve is apparent, and TLR stops increasing at 36 months.

For more information: www.medtronic.com

Related Content

Cordis and Medinol Announce FDA Approval of EluNIR Drug-Eluting Stent System
Technology | Stents Drug Eluting| December 13, 2017
Cordis, a Cardinal Health company, and Medinol recently announced U.S. Food and Drug Administration (FDA) approval of...
The Xience Sierra stent.
Technology | Stents Drug Eluting| November 09, 2017
November 9, 2017 — Abbott received European CE mark for Xience Sierra, the newest generation of the company's Xience
Synergy Stent With Shorter DAPT Superior to Bare-Metal Stent in Elderly Patients
News | Stents Drug Eluting| November 06, 2017
November 6, 2017 — Elderly patients undergoing...
Biotronik Orsiro DES Shows Low Five-Year Event Rates
News | Stents Drug Eluting| November 03, 2017
November 3, 2017 — Biotronik's Orsiro...
Three-Month DAPT Non-Inferior for ACS Patients Treated With Combo Dual Therapy Stent

Image courtesy of OrbusNeich

News | Stents Drug Eluting| November 01, 2017
OrbusNeich reported results from the REDUCE trial in the Late-Breaking Clinical Trial session at the 29th annual...
News | Stents Drug Eluting| October 25, 2017
Elixir Medical Corp. announced it will unveil a new metallic drug-eluting stent (DES) platform at this year’s...
Biotronik's Orsiro Drug-Eluting Stent Outperforms Xience in BIOFLOW-V Trial
News | Stents Drug Eluting| September 01, 2017
September 1, 2017 — Biotronik recently announced data from the BIOFLOW-V randomized trial comparing Orsiro and Xience
First Pennsylvania Patient Treated in LEADERS FREE II Trial of BioFreedom Drug-Coated Stent
News | Stents Drug Eluting| May 12, 2017
PinnacleHealth CardioVascular Institute enrolled the first patient in Pennsylvania in a trial assessing the safety and...
Resolute Onyx DES, drug eluting stent, medtronic, gains FDA approval
Technology | Stents Drug Eluting| May 01, 2017
May 1, 2017 — The U.S.
Videos | Stents Drug Eluting| May 01, 2017
This video, provided by Medtronic, demonstrates the Resolute Onyx coronary stent.
Overlay Init